Literature DB >> 8506958

Accelerated atherosclerosis in hyperlipidemic C57BL/6 mice treated with cyclosporin A.

E E Emeson1, M L Shen.   

Abstract

We and others have demonstrated that T lymphocytes are prominent components of atherosclerotic lesions. We hypothesized that if T cells were necessary for the development of atherosclerosis it would be possible to demonstrate its prevention or retardation in T-cell-suppressed mice. To test this hypothesis, CyA, a potent suppressor of T-cell activation, was used to treat C57BL/6 mice undergoing lipid hyperalimentation. Mice receiving normal mouse chow were completely free of atherosclerotic lesions. In mice receiving the atherogenic diet plus control oil injections, lesions of the aorta and coronary arteries were observed at 135 days and increased progressively in area until 310 days. Somewhat surprisingly, mice given the atherogenic diet plus CyA injections displayed even larger lesions at all three observed time intervals. Although CyA did suppress T-cell reactivity sufficiently to obtain the expected prolongation of skin allografts, it did not suppress the development or progression of atherosclerotic lesions.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8506958      PMCID: PMC1887004     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  39 in total

1.  Organ-specific autoimmune disease induced in mice by elimination of T cell subsets. V. Neonatal administration of cyclosporin A causes autoimmune disease.

Authors:  S Sakaguchi; N Sakaguchi
Journal:  J Immunol       Date:  1989-01-15       Impact factor: 5.422

2.  Atherosclerotic lesions in humans. In situ immunophenotypic analysis suggesting an immune mediated response.

Authors:  A C van der Wal; P K Das; D Bentz van de Berg; C M van der Loos; A E Becker
Journal:  Lab Invest       Date:  1989-08       Impact factor: 5.662

3.  Experimental cyclosporin hypertension: characterization of the rat model.

Authors:  S Lustig; N Stern; M S Golub; P Eggena; J Barrett; D B Lee
Journal:  Transplant Proc       Date:  1989-02       Impact factor: 1.066

4.  Effects of cyclosporine therapy on plasma lipoprotein levels.

Authors:  C M Ballantyne; E J Podet; W P Patsch; Y Harati; V Appel; A M Gotto; J B Young
Journal:  JAMA       Date:  1989-07-07       Impact factor: 56.272

5.  Detection of activated T lymphocytes in the human atherosclerotic plaque.

Authors:  G K Hansson; J Holm; L Jonasson
Journal:  Am J Pathol       Date:  1989-07       Impact factor: 4.307

6.  Frequency of hypercholesterolemia after cardiac transplantation.

Authors:  J S Stamler; D E Vaughan; M A Rudd; G H Mudge; J Kirshenbaum; P Young; R W Alexander; J Loscalzo
Journal:  Am J Cardiol       Date:  1988-12-01       Impact factor: 2.778

7.  Suppression by cyclosporine of cellular and humoral reactivity after peripheral nerve allografts in mice.

Authors:  O Ishida; M Ochi; Y Miyamoto; Y Kuta; M Akiyama
Journal:  Transplantation       Date:  1989-11       Impact factor: 4.939

8.  T cell differentiation in athymic nude rats (rnu/rnu): demonstration of a distorted T cell subset structure by flow cytometry analysis.

Authors:  R Schwinzer; H J Hedrich; K Wonigeit
Journal:  Eur J Immunol       Date:  1989-10       Impact factor: 5.532

9.  Cyclosporine, low-density lipoprotein, and cholesterol.

Authors:  P C de Groen
Journal:  Mayo Clin Proc       Date:  1988-10       Impact factor: 7.616

10.  Hypomagnesaemia, hypoalbuminaemia and plasma lipid changes in rats following the oral administration of ciclosporin.

Authors:  G O Evans
Journal:  Comp Biochem Physiol C       Date:  1988
View more
  16 in total

Review 1.  Immunology of atherosclerosis: the promise of mouse models.

Authors:  A H Lichtman; M Cybulsky; F W Luscinskas
Journal:  Am J Pathol       Date:  1996-08       Impact factor: 4.307

2.  The effects of total lymphocyte deficiency on the extent of atherosclerosis in apolipoprotein E-/- mice.

Authors:  A Daugherty; E Puré; D Delfel-Butteiger; S Chen; J Leferovich; S E Roselaar; D J Rader
Journal:  J Clin Invest       Date:  1997-09-15       Impact factor: 14.808

3.  Suppressive effects of anti-inflammatory agents on human endothelial cell activation and induction of heat shock proteins.

Authors:  A Amberger; M Hala; M Saurwein-Teissl; B Metzler; B Grubeck-Loebenstein; Q Xu; G Wick
Journal:  Mol Med       Date:  1999-02       Impact factor: 6.354

4.  Immune-deficient mice develop typical atherosclerotic fatty streaks when fed an atherogenic diet.

Authors:  A I Fyfe; J H Qiao; A J Lusis
Journal:  J Clin Invest       Date:  1994-12       Impact factor: 14.808

Review 5.  Emerging cross-regulatory roles of immunity and autoimmunity in atherosclerosis.

Authors:  J George; D Harats; B Gilburd; Y Shoenfeld
Journal:  Immunol Res       Date:  1996       Impact factor: 2.829

Review 6.  Adaptive immunity and atherosclerosis: mouse tales in the AJP.

Authors:  Andrew H Lichtman
Journal:  Am J Pathol       Date:  2012-11-16       Impact factor: 4.307

7.  Mildly oxidized low-density lipoproteins decrease early production of interleukin 2 and nuclear factor kappaB binding to DNA in activated T-lymphocytes.

Authors:  S Caspar-Bauguil; J Tkaczuk; M J Haure; M Durand; J Alcouffe; M Thomsen; R Salvayre; H Benoist
Journal:  Biochem J       Date:  1999-01-15       Impact factor: 3.857

8.  The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice.

Authors:  Piers Davenport; Peter G Tipping
Journal:  Am J Pathol       Date:  2003-09       Impact factor: 4.307

9.  CD4+ mononuclear cells induce cytokine expression, vascular smooth muscle cell proliferation, and arterial occlusion after endothelial injury.

Authors:  W W Hancock; D H Adams; L R Wyner; M H Sayegh; M J Karnovsky
Journal:  Am J Pathol       Date:  1994-11       Impact factor: 4.307

10.  Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis.

Authors:  W Palinski; E Miller; J L Witztum
Journal:  Proc Natl Acad Sci U S A       Date:  1995-01-31       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.